Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 2172
- Registration Number
- NCT03926091
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳The First Bethune Hospital of Jilin University (The First Hospital of Jilin University), Changchun, Jilin, China
🇨🇳The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Breast Cancer Treatment Based on Organ-like Culture
- Conditions
- Breast Cancer Organoids
- Interventions
- Drug: TrastuzumabDrug: Doxorubicin HydrochlorideDrug: Epirubicin hydrochlorideDrug: FluorouracilDrug: PaclitaxelDrug: GemcitabineDrug: CisplatinDrug: Recombinant Human EndostatinDrug: Pirarubicin hydrochlorideDrug: PyrrolidineDrug: IxabepiloneDrug: Tamoxifen citrateDrug: Vinorelbine tartrateDrug: CarboplatinDrug: MethotrexateDrug: Eribulin mesylateDrug: Toremifene citrateDrug: AnastrozoleDrug: LetrozoleDrug: ExemestaneDrug: FulvestrantDrug: OlaparibDrug: BevacizumabDrug: Apatinib mesylateDrug: PattozumabDrug: CapecitabineDrug: Ear particlesDrug: Aidi InjectionDrug: Cyclophosphamide
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT03925233
- Locations
- 🇨🇳
JingSu, Xi'an, Shaanxi, China
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
- Conditions
- MRD-positiveAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 19
- Registration Number
- NCT03919526
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
- Conditions
- Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVB Gastric Cancer AJCC v8Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Gastric AdenocarcinomaPostneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT03918499
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Texas Oncology at Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaB Lymphoblastic LymphomaDown Syndrome
- Interventions
- Drug: Asparaginase Erwinia chrysanthemiDrug: CyclophosphamideBiological: BlinatumomabDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: Mercaptopurine Oral SuspensionDrug: MethotrexateDrug: PegaspargaseRadiation: Radiation TherapyDrug: PrednisoneDrug: PrednisoloneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6720
- Registration Number
- NCT03914625
- Locations
- 🇨🇦
IWK Health Centre, Halifax, Nova Scotia, Canada
🇨🇦McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
- Conditions
- Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 8
- Registration Number
- NCT03912831
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: CarfilzomibDrug: CyclophosphamideDrug: DexamethasoneDrug: Granulocyte Colony-Stimulating Factor
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 18
- Registration Number
- NCT03909412
- Locations
- 🇺🇸
Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
- Conditions
- Chronic Granulomatous Disease
- Interventions
- Drug: BusulfanDrug: AlemtuzumabDrug: CyclophosphamideDrug: SirolimusRadiation: Total Body IrradiationBiological: Allogeneic peripheral blood stem cell
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2024-10-30
- Target Recruit Count
- 30
- Registration Number
- NCT03910452
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
- Conditions
- MesotheliomaMesotheliomas PleuralMesothelioma PeritoneumCholangiocarcinomaNon Small Cell Lung CancerMesothelioma, MalignantMesothelioma; PleuraCholangiocarcinoma RecurrentOvarian CancerNon Small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- TCR2 Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT03907852
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Duke University, Durham, North Carolina, United States
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
- Conditions
- Richter Syndrome
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 105
- Registration Number
- NCT03899337
- Locations
- 🇬🇧
Leicester Royal Infirmary, Leicester, United Kingdom
🇬🇧University College London Hospital, London, United Kingdom
🇬🇧University Hospital of Wales, Cardiff, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.